Evidence map›Paper›PMID 34995824›Full record

ArticleResearch in veterinary science2022

Biocompatibility of the fiberoptic microneedle device chronically implanted in the rat brain.

Yukitaka Kani, Jonathan Hinckley, John L Robertson, Jason M Mehta, Christopher G Rylander, John H Rossmeisl

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research in veterinary science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yukitaka KaniVeterinary and Comparative Neurooncology Laboratory and Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA; Department of Mechanical Engineering, University of Texas at Austin, Austin, TX, USA.
Jonathan HinckleyVeterinary and Comparative Neurooncology Laboratory and Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA; Department of Mechanical Engineering, University of Texas at Austin, Austin, TX, USA.
John L RobertsonVeterinary and Comparative Neurooncology Laboratory and Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA; Department of Mechanical Engineering, University of Texas at Austin, Austin, TX, USA.
Jason M MehtaVeterinary and Comparative Neurooncology Laboratory and Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA; Department of Mechanical Engineering, University of Texas at Austin, Austin, TX, USA.
Christopher G RylanderVeterinary and Comparative Neurooncology Laboratory and Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA; Department of Mechanical Engineering, University of Texas at Austin, Austin, TX, USA.
John H RossmeislVeterinary and Comparative Neurooncology Laboratory and Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA; Department of Mechanical Engineering, University of Texas at Austin, Austin, TX, USA. Electronic address: jrossmei@vt.edu.
The University of Texas at Austin · USVirginia–Maryland College of Veterinary Medicine · USVirginia Tech · US

Funding

Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBMP01CA207206 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DEBINSKI, WALDEMAR · 2017 to 2021
$9.0M
Multi-receptor Targeting of GlioblastomaR01CA256285 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Waldemar Debinski · 2021 to 2026
$2.8M
NCI NIH HHS P01 CA207206NCI NIH HHS R01 CA256285
6 · The paper itself

Abstract

The fiberoptic microneedle device (FMD) is a fused-silica microcatheter capable of co-delivery of fluids and light that has been developed for convection-enhanced delivery and photothermal treatments of glioblastoma. Here we investigate the biocompatibility of FMD fragments chronically implanted in the rat brain in the context of evaluating potential mechanical device failure. Fischer rats underwent craniectomy procedures for sham control (n = 16) or FMD implantation (n = 16) within the brain. Rats were examined daily after implantation, and at 14, 30, 90, and 180 days after implantation were evaluated via computed tomography of the head, hematologic and blood biochemical profiling, and necropsy examinations. Clinical signs of illness and distant implant migration were not observed, and blood analyses were not different between control and FMD implanted groups at any time. Mild inflammatory and astrogliotic reactions localized to the treatment sites within the brain were observed in all groups, more robust in FMD implanted groups compared to controls at days 30 and 90, and decreased in severity over days 90-180 of the study. One rat developed a chronic, superficial surgical site pyogranuloma attributed to the FMD silica implant. Chronically implanted FMD fragments were well tolerated clinically and resulted in anticipated mild, localized brain tissue responses that were comparable with other implanted biomaterials in the brain.

Indexed as

Biocompatible MaterialsNeedlesAnimalsBrainProstheses and ImplantsRatsBiocompatible MaterialsBrainConvection enhanced deliveryFiberoptic microneedle deviceNeurotoxicology

Identifiers

PMID34995824
PMCPMC8858887
OpenAlexW4206438491

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.